Holen Sie sich die Stockscreener-App
165.27
0.28%
0.32
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca (AZN) Results Check: EPS Prints Above Forecast on the Day; Market Reaction: The Market Price Advances 3.03% at the CloseEarnings Season Outlook - Vinanet
7,500 Shares in Astrazeneca Plc $AZN Bought by Westport Asset Management Inc. - MarketBeat
AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating - marketscreener.com
Is It Too Late to Buy AstraZeneca PLC (AZN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send? - TradingKey
AstraZeneca Expands Respiratory Pipeline With New China Trial for Chronic Lung Infections - TipRanks
Rumors of AstraZeneca-Bristol-Myers merger fade; focus shifts to each firm's strengths in cancer and immune diseases. - Pluang
AstraZeneca (AZN) CFO’s share award vests at £114.60 a share - Stock Titan
AstraZeneca Vs. Bristol-Myers Squibb: Who’s The Better Bargain For Investors (NYSE:BMY) - Seeking Alpha
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig - European Biotechnology Magazine
Is AstraZeneca (LSE:AZN) Becoming the Quiet Anchor of a Jittery London Market? - Kalkine Media
Why Is Large Pharmaceutical Pipelines During Broader Market Uncertainty Active In London Today? - Kalkine Media
AstraZeneca CFO Receives First Vesting Under Long-Term Performance Share Plan - TipRanks
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca PLC : UBS reiterates its Buy rating - marketscreener.com
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates - Proactive financial news
AstraZeneca stock edges higher as Q2 2026 growth and EPS gains offset lung cancer trial setback - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Anchoring London's Healthcare Trade Today? - Kalkine Media
AstraZeneca’s win in lung cancer; Sandoz inks a China deal - Yahoo Finance
Did AstraZeneca's (LSE:AZN) Lung Cancer Data Just Reset The Blue-Chip Mood Today? - Kalkine Media
AstraZeneca stock rises on lung cancer trial news - AD HOC NEWS
Can AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Turn Regulatory Review Into Durable Progress? - Kalkine Media
Can Shell (LSE:SHEL) And AstraZeneca (LSE:AZN) Turn Capital Allocation Into Durable Progress? - Kalkine Media
Health Care Down on Growth DoubtsHealth Care Roundup - marketscreener.com
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
These UK Stocks Are Undervalued After Earnings - Morningstar
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch - Yahoo Finance
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda - finance.biggo.com
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant - Yahoo Finance UK
AstraZeneca ditches lung cancer treatment trial - Yahoo Finance UK
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer - BioPharma Dive
UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials - marketscreener.com
AstraZeneca stock gains on lung cancer trial news - ad-hoc-news.de
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - Benzinga
Market Wrap: EU chip stocks surge on Anthropic's earnings! AstraZeneca halts trials for lung cancer therapy (17.08.2026) - XTB.com
AstraZeneca (AZN) drug delays progression in first-line HER2 lung cancer - Stock Titan
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda - Clinical Trials Arena
AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely - Stock Titan
Lung cancer trial success puts AstraZeneca (AZN) drug duo in play - Stock Titan
Plato Investment Management Ltd Takes $5.90 Million Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC : JP Morgan remains its Buy rating - marketscreener.com
AstraZeneca halts lung cancer trial in fresh pipeline setback - Proactive financial news
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update - marketscreener.com
FTSE 100 Gains Support From Miners, AstraZeneca And Rolls-Royce - DirectorsTalk Interviews
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 36.59% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca Stops Cancer Drug Trial as Success Seen Unlikely - Bloomberg.com
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu - Yahoo Finance UK
AstraZeneca halts lung trial as two cancer drugs show positive results - marketscreener.com
AstraZeneca (LSE:AZN) Puts Blue-Chip Stocks Under An Earnings-Quality Spotlight - Kalkine Media
AstraZeneca Reports Positive Results with Lung Cancer Drugs - marketscreener.com
AstraZeneca scraps late-stage lung cancer trial after data setback - Investing.com Nigeria
Why is AstraZeneca stock up today? By Investing.com - Investing.com UK
Triple news for AstraZeneca - marketscreener.com
AstraZeneca reports Phase III survival benefit for Tagrisso–Orpathys lung cancer combination - Yahoo Finance UK
AstraZeneca, Daiichi Sankyo's Enhertu Improves Progression-free Survival in Late-stage Lung Cancer Trial - marketscreener.com
AstraZeneca discontinues lung cancer trial of volrustomig - Investing.com Nigeria
AstraZeneca ends one trial; Telecom Plus backs view - marketscreener.com
AstraZeneca lung cancer drug combination extends survival in trial - Proactive financial news
AstraZeneca discontinues lung cancer trial of volrustomig By Investing.com - Investing.com UK
AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer - Investing.com Nigeria
AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination - DirectorsTalk Interviews
AstraZeneca Ends Late-stage Metastatic Non-small Cell Lung Cancer Trial - marketscreener.com
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):